HLOSF Financials: Healios K.K. AI Analysis



Financials

HLOSF Financial

Healios K.K.

$1.8

At close: Aug 06, 16:00:00 GMT-4

$1.8

Pre-market: Aug 07, 05:07:42 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$1.8

Open

$1.8

Day's Range

$1.8 - $1.8

52 week range

$1.8 - $4.45

Volume

100

Avg.Volume

Dividend yield

EPS (TTM)

-0.16

Market Cap

$243.0M

What is HEALIOS K K?

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 75 full-time employees. The company went IPO on 2015-06-16. The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	74	8	25	19	22	38
Revenue Growth (YoY)	-87%	-79%	39%	-44%	-96%	280%
Cost of Revenue	--	--	76	45	68	29
Gross Profit	--	--	-51	-26	-46	9
Selling, General & Admin	1,329	354	469	271	235	290
Research & Development	2,340	798	491	467	584	482
Operating Expenses	3,800	1,138	956	734	783	753
Other Non Operating Income (Expenses)	0	-1	1	1	-1	--
Pretax Income	-3,011	-3,464	2,009	569	-2,125	-2,579
Income Tax Expense	112	-7	92	6	21	-16
Net Income	-3,133	-3,478	1,929	564	-2,148	-2,562
Net Income Growth	-28%	36%	654%	-137%	302%	6%
Shares Outstanding (Diluted)	125.79	125.79	115.62	114.7	104.4	95.87
Shares Change (YoY)	31%	31%	28%	27%	16%	15%
EPS (Diluted)	-24.9	-27.64	16.68	4.92	-20.57	-26.72
EPS Growth	-45%	3%	487%	-129%	247%	-8%
Free Cash Flow	-3,865	-1,306	-931	-808	-820	-774
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	-204%	-136.84%	-209.09%	23.68%
Operating Margin	-5,035.13%	-14,125%	-4,028%	-4,000%	-3,768.18%	-1,957.89%
Profit Margin	-4,233.78%	-43,475%	7,716%	2,968.42%	-9,763.63%	-6,742.1%
Free Cash Flow Margin	-5,222.97%	-16,325%	-3,724%	-4,252.63%	-3,727.27%	-2,036.84%
EBITDA	-3,449	-1,060	-935	-692	-762	-676
EBITDA Margin	-4,660.81%	-13,250%	-3,740%	-3,642.1%	-3,463.63%	-1,778.94%
D&A For EBITDA	277	70	72	68	67	68
EBIT	-3,726	-1,130	-1,007	-760	-829	-744
EBIT Margin	-5,035.13%	-14,125%	-4,028%	-4,000%	-3,768.18%	-1,957.89%
Effective Tax Rate	-3.71%	0.2%	4.57%	1.05%	-0.98%	0.62%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

Revenue Growth (YoY)

-87%

-79%

39%

-44%

-96%

280%

Cost of Revenue

Gross Profit

-51

-26

-46

Selling, General & Admin

1,329

354

469

271

235

290

Research & Development

2,340

798

491

467

584

482

Operating Expenses

3,800

1,138

956

734

783

753

Other Non Operating Income (Expenses)

-1

Pretax Income

-3,011

-3,464

2,009

569

-2,125

-2,579

Income Tax Expense

112

-7

-16

Net Income

-3,133

-3,478

1,929

564

-2,148

-2,562

Net Income Growth

-28%

36%

654%

-137%

302%

Shares Outstanding (Diluted)

125.79

115.62

114.7

104.4

95.87

Shares Change (YoY)

31%

28%

27%

16%

15%

EPS (Diluted)

-24.9

-27.64

16.68

4.92

-20.57

-26.72

EPS Growth

-45%

487%

-129%

247%

-8%

Free Cash Flow

-3,865

-1,306

-931

-808

-820

-774

Free Cash Flow Per Share

Gross Margin

-204%

-136.84%

-209.09%

23.68%

Operating Margin

-5,035.13%

-14,125%

-4,028%

-4,000%

-3,768.18%

-1,957.89%

Profit Margin

-4,233.78%

-43,475%

7,716%

2,968.42%

-9,763.63%

-6,742.1%

Free Cash Flow Margin

-5,222.97%

-16,325%

-3,724%

-4,252.63%

-3,727.27%

-2,036.84%

EBITDA

-3,449

-1,060

-935

-692

-762

-676

EBITDA Margin

-4,660.81%

-13,250%

-3,740%

-3,642.1%

-3,463.63%

-1,778.94%

D&A For EBITDA

277

EBIT

-3,726

-1,130

-1,007

-760

-829

-744

EBIT Margin

-5,035.13%

-14,125%

-4,028%

-4,000%

-3,768.18%

-1,957.89%

Effective Tax Rate

-3.71%

0.2%

4.57%

1.05%

-0.98%

0.62%

Follow-Up Questions

What are Healios K.K.'s key financial statements?



According to the latest financial statement (Form-10K), Healios K.K. has a total asset of $0, Net loss of $0

What are the key financial ratios for HLOSF?



Healios K.K.'s Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Healios K.K.'s revenue broken down by segment or geography?



Healios K.K. largest revenue segment is Pharmaceutical, at a revenue of 104,000,000 in the most earnings release.For geography, Japan is the primary market for Healios K.K., at a revenue of 90,000,000.

Is Healios K.K. profitable?



no, according to the latest financial statements, Healios K.K. has a net loss of $0

Does Healios K.K. have any liabilities?



no, Healios K.K. has liability of 0

How many outstanding shares for Healios K.K.?



Healios K.K. has a total outstanding shares of 0

Healios K.K. (HLOSF) Financial

HLOSF Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is HEALIOS K K?

Healios K.K. (HLOSF) Financial

HLOSF Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is HEALIOS K K?

HLOSF Income

Follow-Up Questions

What are Healios K.K.'s key financial statements?

What are the key financial ratios for HLOSF?

How is Healios K.K.'s revenue broken down by segment or geography?

Is Healios K.K. profitable?

Does Healios K.K. have any liabilities?

How many outstanding shares for Healios K.K.?